PharmaTher Has Secured North American Distribution Rights
The company will become the exclusive distributor for the Craft Health pharmaceutical 3D printing platform.
Updated on Oct. 3, 2026 in Healthcare
Live Poll
Do you believe personalized, 3D-printed medicine will improve the quality of your healthcare?
PharmaTher has entered into a distribution agreement to serve as the exclusive provider of the Craft Health pharmaceutical 3D printing platform in North America. The deal encompasses printers, software, consumables, and service support.
Why it matters
The collaboration introduces advanced 3D printing capabilities to compounding pharmacies, hospitals, and research institutions across the region. It seeks to integrate specialized pharmaceutical manufacturing hardware into existing healthcare and biotechnology infrastructure.
PharmaTher has identified more than 10,000 potential placement sites for the Craft Health platform across North America. Each installed system is expected to generate recurring revenue for the company.
The players
PharmaTher
This company is a provider of specialized pharmaceutical and biotechnology solutions.
Craft Health
Based in Singapore, this organization specializes in pharmaceutical 3D printing technology.
The details
PharmaTher will manage the full lifecycle of the CraftMake printing platform, including installation, staff training, system validation, and ongoing service. The partnership extends to a broad range of clients, including telehealth firms, government agencies, and CDMOs.
Timeline
PharmaTher plans to place initial orders for the printing platform in Q4 2026.
Market Landscape
The partnership follows the trend of decentralized pharmaceutical manufacturing by bringing advanced printing capabilities directly into local clinical and research settings. This move positions PharmaTher to capture market share by integrating specialized hardware into existing supply chains.
Hospitals and pharmacies may see increased access to on-site medication production and customized pharmaceutical compounding. The shift could eventually lead to faster turnaround times for specialized drug therapies within the North American market.
The takeaway
The adoption of 3D printing technology marks a significant move toward localized pharmaceutical production. Businesses in the sector should monitor how this hardware integration affects regional supply chain efficiency.
Further reading
Learn more about the latest innovations in Healthcare.
Source note: This article includes information reported by VoxelMatters - The heart of additive manufacturing.
Live Poll
Do you believe personalized, 3D-printed medicine will improve the quality of your healthcare?
